Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus

NCT02597049 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02597049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02597049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Parallel-Arm, Double-Blind Study of Efficacy and Safety of Dulaglutide When Added to SGLT2 Inhibitors in Patients With Type 2 Diabetes Mellitus
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2015
Completion date
February 28, 2017
Enrollment
424 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus